This CDC report detailed 46 cases of suspected donor-derived KSHV-related complications among 153 transplant recipients from 2021-2025, roughly five times the number of cases reported from 2016-2020.

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

After surviving Ewing Sarcoma, 14-year-old Jude Baker used his Make-A-Wish not for a trip, but to help people experiencing ...

More than 400 cartons of Nilotinib capsules were voluntarily recalled by Cipla USA after failing manufacturing specifications ...

South University (SU) is proud to highlight a powerful example of its mission in action, as faculty from the SU Tampa ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

PARIS, FRANCE, 09 March 2026 ? Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

Lilly Warren, whose family benefited in 2018, now volunteers with Inheritance of Hope at its Legacy Retreats for families ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.